Collectively, we strongly believe that the 11 drugs, except Camostat and Nafamostat, evaluated in this study are promising noncovalent TMPRSS2 inhibitors, and their potency for COVID-19 treatment could be further investigated. Here, TMPRSS2 is linked to COVID-19.